Taiwan Liposome Company, Ltd. (TLC) stock prices were up by 34.95% shortly after the market opened on May 25th, 2021, bringing the price per share up to USD$6.68 shortly after the trading day commenced.
Indian Approval for AmphoTLC
TLC announced on May 25th, 2021 that the Central Drugs Standard Control Organization (CDSCO) of India had approved the New Drug Application (NDA) for Amphotericin B Liposome for Injection (
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
About AmphoTLC
AmphoTLC is a pioneer complex generic drug that has achieved bioequivalences to Gilead’s AmBisome, consolidating its sameness to the safest form of amphotericin B in the world. With the approval and prompt delivery of the drug, TLC will afford thousands of patients the opportunity to receive early treatment with AmphoTLC. This development is forecasted to reduce the fatality rate brought on by the sudden influx of mucormycosis.
AmphoTLC Proliferation
AmphoTLC is a treatment for severe fungal infections, including, but not limited to, mycormycosis. The drug has been approved in Taiwan and has been marketed and sold for several years, exhibiting a steady increase in market share year over year. Market authorization of the drug in the Chinese market is currently under review. The approval in India comes after the conduct of complete due diligence by Indian regulators, based on several years of development by TLC as well as the drug quality performance in the developed markets.
Prevalence of CAM
As the Covid-19 pandemic continues raging across India, the number of
CAM Situation in India
The steady rise of CAM cases has resulted in unprecedented volumes of demand for TLC’s proprietary drug, triggering an acute shortage. The situation is further complicated by the proliferation of the treatment on the black market for three times its retail price. The sharp inflation and the financial burden incurred for patients has resulted in many patients opting for the conventional amphotericin B. This treatment is known for its nephrotoxicity, and many patients end up discontinuing usage due to renal toxicities.
Future Outlook for TLC
With promising prospects of a foray into the vast Indian market, TLC is poised to capitalize on the increased commercialization of AmphoTLC. Current and potential investors are hopeful that the company will continue to leverage the resources at its disposal to continue expanding into global markets to facilitate significant and sustained increases in shareholder value.
